All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABBV-3373
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
Data show the clinical activity of ABBV-3373 and support advancing the development of the platform in rheumatoid arthritis and initiating clinical studies in other immune-mediated diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RSLV-132
Therapeutic Area: Immunology Product Name: RSLV-132
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
The Phase 2 study demonstrated a clinically meaningful improvement in four separate, independent, validated measures of fatigue in the RSLV-132 group, but not the placebo group.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $29.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 01, 2020
Details:
The final closing of the Series B financing will support the advancement of an innovative fermentation production platform to develop and manufacture both “standard” high-richness, high-diversity fermented product MaaT013, and a pipeline of indication-specific candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Persavita's experimental product is composed of three natural ingredients with known immune modulating properties. The company is gearing up to test this experimental product in Covid-19 patients through a phase 2 clinical study already authorized by Health Canada.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mezagitamab
Therapeutic Area: Immunology Product Name: TAK-079
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2020
Details:
Xoma has earned a $2 million milestone payment from Takeda upon dosing first patient in its Phase 2 safety, tolerability, and efficacy study of mezagitamab (TAK-079) in generalized myasthenia gravis. Xoma may receive up to $16 M in additional millstone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EXE-346
Therapeutic Area: Immunology Product Name: EXE-346
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
EXE-346 is an LBP which contains a fixed-proportion of 8 strains of live probiotic bacteria which are intended for oral administration. EXE-346 is intended to decrease this inflammation of the pouch and prevent active disease flare-ups.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABY-035
Therapeutic Area: Immunology Product Name: ABY-035
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The study is a multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial in patients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Burixafor
Therapeutic Area: Immunology Product Name: TG-0054
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: GPCR Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2020
Details:
Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
